ONCOSEC MEDICAL INCORPORATED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0003 USD | 0.00% |
|
0.00% | 0.00% |
| 2023 | Motion for Asset Sale Approved for OncoSec Medical Incorporated | CI |
| 2023 | Motion for Asset Sale Filed by OncoSec Medical Incorporated | CI |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to the OncoSec Medic...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
OncoSec Medical Incorporated is a late-stage immuno-oncology company. The Company is focused on designing, developing and commercializing intra-tumoral DNA-based therapeutics delivered by electroporation (EP) to stimulate and augment anti-tumor immune responses for the treatment of cancers. Its core technology, ImmunoPulse, is a drug-device therapeutic modality platform comprised of an OncoSec Medical System EP device (the OMS EP Device) and a DNA plasmid delivery and application method that enables transient expression of recombinant therapeutic molecules in cells. The OMS EP Device is designed to promote cellular uptake of plasmid DNA injected directly into solid tumors to allow subsequent expression of the encoded therapeutic protein. The OMS EP Device can be adapted to treat different tumor types and consists of an electrical pulse generator and a disposable applicator. Its lead product candidate, tavokinogene telseplasmid (TAVO), is a plasmid encoding human interleukin-12.
Calendar
2025-03-11
- Q2 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 1.79K | |
| +23.69% | 46.71B | |
| +48.83% | 41.8B | |
| -1.16% | 41.52B | |
| -3.42% | 29.55B | |
| +10.50% | 25.78B | |
| -21.05% | 19.26B | |
| -0.06% | 12.14B | |
| -1.08% | 12.08B | |
| +26.34% | 11.98B |
- Stock Market
- Equities
- ONCSQ Stock
- News OncoSec Medical Incorporated
- Transcript : OncoSec Medical Incorporated - Special Call